Condition: High Grade Glioma · Ependymoma · Embryonal Tumor of Brain · Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
The goal of this clinical trial is to learn if intratumoral administration of DNX-2401 works to treat recurrent and refractory high grade brain tumors in children and young adults. It will also learn about the safety of DNX-2401. The main questions it aims to answer are: * Does a single intratumoral administration of DNX-2401 elicit tumor response and improve survival? * Is a single intratumoral administration of DNX-2401 safe and well tolerated? Participants will: * Undergo surgery for tumor biopsy followed by a single intratumoral administration of DNX-2401 * Visit the clinic periodically for checkups and tests
This description comes directly from the study's public registry record.
Jaime Gállego Pérez de Larraya, M.D., Ph.D. · +34 948 25 54 00 · jgallego@unav.es
Central Unit for Clinical Trials · +34 948 25 54 00 · ucicec@unav.es
Always discuss trial participation with your own doctor first.
| Princess Máxima Centrum | Utrecht, Netherlands | Not Yet Recruiting |
| Cancer Center Clínica Universidad de Navarra | Pamplona, Navarre, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07424092